Form 4: TriSalus Life Sciences: Executive Stock Grant and Option Award

TriSalus Life Sciences, Inc. reports a significant stock grant and option award to Chief Medical Officer Richard Henry Marshall.

Summary

• Richard Henry Marshall, Chief Medical Officer of TriSalus Life Sciences, Inc., received a grant of 60,000 restricted stock units (RSUs) and was awarded an employee stock option to purchase 120,000 shares.
• The RSUs are scheduled to vest in four equal annual installments starting on June 29, 2026, contingent upon continued service.
• The stock option has an exercise price of $4.74 per share and vests over time, with one-fourth vesting on June 29, 2027, and the remainder vesting monthly thereafter, also subject to continued service.
• Following these transactions, Marshall beneficially owns 90,000 shares of common stock directly and an additional 253,000 shares indirectly through the stock option.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents standard executive compensation practices rather than significant financial performance or strategic shifts.

Positives

• Grant of 60,000 restricted stock units to the Chief Medical Officer, indicating a commitment to retaining key talent.
• Award of employee stock options for 120,000 shares, aligning executive incentives with potential future stock price appreciation.
• The vesting schedules for both RSUs and stock options are tied to continued service, promoting long-term employee retention.

Negatives

• No immediate financial gain is reported, as the RSUs and options are subject to future vesting and exercise conditions.

Risks

• The value of the RSUs and stock options is subject to the future performance and stock price of TriSalus Life Sciences, Inc.
• Continued service is a condition for vesting, meaning any departure from the company before vesting dates would result in forfeiture of unvested awards.

Future Outlook

The future outlook for the granted RSUs and stock options is contingent on the continued service of Richard Henry Marshall and the future performance of TriSalus Life Sciences, Inc.'s common stock.

Industry Context

StockSavvy.ai notes that the issuance of restricted stock units and stock options to key executives is a common practice in the life sciences industry to incentivize performance and retain talent, especially in companies focused on development and commercialization.

Stakeholder Impact

• Shareholders: The issuance of RSUs and options represents potential future dilution if exercised, but also aligns executive interests with shareholder value creation.
• Employees: Reinforces the company's use of equity-based compensation for key personnel.
• Management: Directly impacts the compensation and potential wealth accumulation of the Chief Medical Officer.

Next Steps

• Continued service by Richard Henry Marshall to meet vesting requirements for RSUs and stock options.
• Potential exercise of stock options by Richard Henry Marshall upon vesting, subject to market conditions and personal financial decisions.

Key Dates

Keywords

Form 4, SEC Filing, TriSalus Life Sciences, TLSI, Stock Options, Restricted Stock Units, Executive Compensation, Beneficial Ownership, Richard Henry Marshall, Chief Medical Officer